Axitinib is an inhibitor of VEGFR that exhibits anticancer chemotherapeutic and anti-angiogenic activities. Axitinib is currently in clinical trials as a potential treatment for renal cell carcinoma. In vitro, axitinib increases levels of CD8+ T cells and decreases levels of myeloid-derived suppressor cells, inhibiting proliferation and increasing apoptosis. In vivo, this compound inhibits expression of iNOS, arginase, IL-6, TNF-α, and IFN-γ, increasing apoptosis and inhibiting tumor growth. In animal models of lung adenocarcinoma, axitinib decreases tumor vasculature and lesion growth.